Tafur GS, Abad ML, Montenegro M, Romero PR

Language: Spanish
References: 28
Page: 315-317
PDF size: 187.14 Kb.

ABSTRACT

Background: The c-kit is a growth factor receptor that is expressed in a variety of tumors as GIST, leukemia, renal tumors, etc, including Ewing’s sarcoma/PNET, this indicates the possible role of this marker in the progression tumor and possible use in treating these malignancies. Investigations initial of inhibitors tirocinasa in development of tumour cells of Ewing’s sarcoma/PNET are promising.
Objective: To evaluate and detect CD117 positive cases of Ewing sarcoma which could benefit from treatment with tyrosine kinase inhibitors.
Material and methods: It is a retrospective study of patients diagnosed with Ewing’s sarcoma at the Hospital Solon Espinosa Ayala, SOLCA of Quito, Ecuador, in the period 2003-2007. We reviewed blocks of tissue in paraffin embedded and were processed with the usual technique of antibodies immunoperoxidase CD99 and CD117. The stain was classified low (+) to intense (+++).
Results: Of the 16 patients studied, all were positive for CD99, which confirmed the diagnosis of Ewing’s sarcoma/PNET; 11 were positive for CD117 (68.75%) and 5 were negative (31.25%). The staining ranged from low (+) to intense (+++), and in all cases were found in the cytoplasm or in the membrane.
Conclusions: We findings compared with those described in world literature are similar, with a margin of 0.8%, so we think that a high percentage of these tumors might benefit from therapeutic strategies with the tyrosine kinasa inhibitors (sunitinib / imatinib).

REFERENCES

1. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F. Protein expression of KIT an gene mutation of C-kit and PDGIRs in Ewing sarcomas. Pathol Res Pract 2007; 203:127-34.

2. Scotlandi K, Manara M, Strammiello R, Landuzzi L, et al. Ckit receptor expressionin Ewing’s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952-60.

3. Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. C kit expressing Ewing tumour cells are insensitive a imatinib mesylate (STI 571). Cancer Chemote Pharmacol 2002;50:167-9.

4. Konty U. Regulation of apoptosis and proliferation in Ewing sarcoma: oportunuties for targeted therapy. Hematol Oncol. 2006;1:14-21.

5. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplant. Pediatric Transplant 2004;8(Supp l):67-82.

6. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use de imatinib en Ewing sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer INST 2002;94:1673-9.

7. Henrich M, Griffith D, Druker B, Wait C, et al. Inhibition of c-kit receptor tirosynkinase activity by STI, a selective tirosynekinase inhibitor. Blood 2000;96;925-932.

8. Kovar H. Ewing tumor biology: perpestives for innovative treatment approaches. Adv Exp Med Biol 2003;532:27-37.

9. Buchdunger E, Cioffi C, Law N, Stover D, et al. ABL proteintirosyne- kinase inhibitorSTI 571 inhibits in vitro signal transduction mediated by c kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.

10. Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: W.B. Saunders, 2006;pp:442-7.

11. Folpe A, Goldblum J, Rubin B, Shehata BM, et al. Morphologic and immunophenotypic diversity in Ewing family tumors. A study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.

12. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, et al. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing sarcoma. Eur J Cancer 2006;421:91-96.

13. Kontny U, Hammerle K, Klein R, Shayan P, et al. Sensitivity of Ewing sarcoma to trail induced apoptosis. Cell Death Differ 2001;8:506-14.

14. Llombart-Bosch A, Contesso G, Peydro-Olaya A. Ultrastructural study of 28 cases of Ewing sarcoma: typical and atypical forms. Cancer 1978;41:1362-73.

15. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F. Protein expression of KIT an gene mutation of C-kit and PDGIRs in Ewing sarcomas. Pathol Res Pract 2007; 203:127-34.

16. Scotlandi K, Manara M, Strammiello R, Landuzzi L, et al. Ckit receptor expressionin Ewing’s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952-60.

17. Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. C kit expressing Ewing tumour cells are insensitive a imatinib mesylate (STI 571). Cancer Chemote Pharmacol 2002;50:167-9.

18. Konty U. Regulation of apoptosis and proliferation in Ewing sarcoma: oportunuties for targeted therapy. Hematol Oncol. 2006;1:14-21.

19. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplant. Pediatric Transplant 2004;8(Supp l):67-82.

20. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use de imatinib en Ewing sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer INST 2002;94:1673-9.

21. Henrich M, Griffith D, Druker B, Wait C, et al. Inhibition of c-kit receptor tirosynkinase activity by STI, a selective tirosynekinase inhibitor. Blood 2000;96;925-932.

22. Kovar H. Ewing tumor biology: perpestives for innovative treatment approaches. Adv Exp Med Biol 2003;532:27-37.

23. Buchdunger E, Cioffi C, Law N, Stover D, et al. ABL proteintirosyne- kinase inhibitorSTI 571 inhibits in vitro signal transduction mediated by c kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.

24. Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: W.B. Saunders, 2006;pp:442-7.

25. Folpe A, Goldblum J, Rubin B, Shehata BM, et al. Morphologic and immunophenotypic diversity in Ewing family tumors. A study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.

26. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, et al. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing sarcoma. Eur J Cancer 2006;421:91-96.

27. Kontny U, Hammerle K, Klein R, Shayan P, et al. Sensitivity of Ewing sarcoma to trail induced apoptosis. Cell Death Differ 2001;8:506-14.

28. Llombart-Bosch A, Contesso G, Peydro-Olaya A. Ultrastructural study of 28 cases of Ewing sarcoma: typical and atypical forms. Cancer 1978;41:1362-73.